Development of bullous pemphigoid during treatment of psoriatic onycho-pachydermo periostitis with ustekinumab
Development of bullous pemphigoid during treatment of psoriatic onycho-pachydermo periostitis with ustekinumab
复制标题
DOI：
10.1111/1346-8138.12943
复制
发表时间：
2015-10-01
影响因子：
3.1
通讯作者：
Shimizu, Hiroshi
中科院分区：
文献类型：
--
作者：
Nakayama, Chihiro;Fujita, Yasuyuki;Shimizu, Hiroshi
Ustekinumab是一种人单克隆抗体，特异性结合白细胞介素(IL)-12和IL-23的p40亚基，抑制这两种细胞因子的活性，从而阻断t -辅助性（Th）1和Th17炎症途径。虽然生物制剂极大地改变了银屑病的治疗策略，但在使用这些制剂期间，自身免疫性疾病的病例有所增加。我们经历了一个病例大疱性类天疱疮发生在治疗银屑病关节炎，银屑病甲厚皮骨膜炎的罕见变种与ustekinumab。包括我们的病例在内，仅有6例自身免疫性水疱疾病在生物制剂治疗期间被报道，我们在此回顾这些病例的已发表的工作。皮肤科医生必须注意在ustekinumab治疗期间自身免疫性水泡疾病的可能性。
Ustekinumab is a human monoclonal antibody that specifically binds to the p40 subunit of interleukin (IL)-12 and IL-23, inhibiting the activity of both cytokines, thereby blocking the T-helper (Th)1 and Th17 inflammatory pathways. While biologic agents have dramatically changed the strategies of psoriasis treatment, increasing cases of autoimmune diseases during the use of such agents have been reported. We experienced a case of bullous pemphigoid occurring during treatment of a rare variant of psoriatic arthritis, psoriatic onycho-pachydermo periostitis with ustekinumab. Only six cases of autoimmune blistering diseases during treatment with biologic agents have ever been reported including our case, and we herein review the published work of these cases. Dermatologists must be attentive to the possibility of autoimmune blistering diseases during ustekinumab treatment.